Introduction
The proteasome is a multienzyme complex found in all eukaryotic cells that functions to orderly degrade more than 80% of ubiquitin-tagged cellular proteins, which control cellular division, growth, function and death. 1, 2 The list of these proteins includes cyclins, cyclin-dependent kinases, cyclin-dependent kinase inhibitors, oncogenes, tumor suppressor genes, and transcriptional activators and inhibitors. 1, 3, 4 In particular, the proteasome plays a major role in activation of the transcription factor nuclear factor-kB (NF-kB) through the degradation of its endogenous inhibitor, I-kB. 5 NF-kB, once activated, translocates from the cytoplasm to the nucleus, where it upregulates the transcription of target genes involved in cell survival, cell adhesion and cytokine signaling.
Timely degradation of regulatory proteins induced by the proteasome is essential for maintaining normal cellular function and homeostasis. 6 In cancer cells, the proteasome is also essential to the mechanisms underlying tumor cell growth, apoptosis, angiogenesis and metastasis, thereby representing a novel target for cancer therapy. 6, 7 Accumulation of important regulatory intracellular proteins (including I-kB, p53 tumor suppressor gene, p21 and p27 cyclin-dependent kinase inhibitors and Bax proapoptotic protein), which occurs as a result of proteasome inhibition, 4, 6 leads to decreased NF-kB activity, increased p53-mediated transcription of genes involved in apoptosis and dysregulation of the cell cycle, increased p21-and p27-mediated induction of cell cycle arrest, and promotion of apoptosis by Bax-mediated inhibition of Bcl-2. 3, 4, 8 Furthermore, inhibition of proteasome function may also reverse mechanisms of resistance to chemotherapy or radiation therapy and increase the sensitivity of tumor cells to conventional chemotherapy or radiotherapy. [9] [10] [11] [12] [13] Results of both preclinical and clinical studies suggest that neoplastic cells are more sensitive to inhibition of the proteasome function than are normal cells. For example, in preclinical studies, malignant B cells from patients with chronic lymphocytic leukemia and transformed fibroblasts were found to be much more sensitive to proteasome inhibition than were normal lymphocytes and non-transformed human lymphoblasts. [13] [14] [15] Similarly, multiple myeloma (MM) cell lines were more sensitive to apoptosis induced by proteasome inhibitors than were peripheral blood mononuclear cells from healthy individuals. 9 Although the biologic basis for the enhanced susceptibility of cancer cells to proteasome inhibitors has not been fully elucidated, several hypotheses have been proposed, including a greater sensitivity of rapidly proliferating tumor cells to proteasome inhibitors and more efficient uptake and slower inactivation of proteasome inhibitors by tumor cells. 3, 4, 6 A large number of compounds, both natural and synthetic, have been shown to inhibit proteasome function by binding to the chymotrypsin-like site of the 20S core catalytic particle. 3, 16 The synthetic inhibitors include peptide aldehydes, peptide vinyl sulfones and dipeptidyl boronic acids. 16 Compared with peptide aldehyde analogs, dipeptidyl boronic acids are much more potent and dissociate more slowly from the proteasome, inducing stable proteasome inhibition. 3, 17 Among peptide boronic acids, the small molecule PS-341 or bortezomib, as a single agent was found to have potent cytotoxicity in a standard National Cancer Institute in vitro screening of 60 cell lines derived from multiple human tumors. 18 Owing to its selectivity, reversible interaction with the proteasome, favorable pharmacokinetics and ease of synthesis, PS-341 has been the first proteasome inhibitor to reach clinical trials in cancer patients.
In MM, adhesion of tumor cells to extracellular matrix proteins and bone marrow stromal cells (BMSCs) plays a major role in the pathogenesis of the disease (Figure 1) . 19 Specifically, adhesion of myeloma cells to extracellular matrix proteins confers cell adhesion-mediated drug resistance, and binding of tumor cells to BMSCs triggers transcription and secretion of cytokines, primarily NF-kB-dependent secretion of interleukin (IL)-6. This in turn triggers the proliferation of myeloma cells, promotes both myeloma cell survival and upregulation of antiapoptotic molecules, confers to tumor cells further resistance to conventional therapy, and induces vascular endothelial growth factor (VEGF) expression and secretion. 9, [20] [21] [22] [23] [24] Because proteasome inhibitors have been shown to inhibit myeloma cell-stromal cell interaction, to interfere with NF-kB-dependent induction of cytokine secretion, and to exert antiangiogenic activity, 9, [25] [26] [27] MM is likely to be an ideal target for in vivo proteasome inhibitor therapy ( Figure 2 ). 27 Preclinical studies with PS-341 (bortezomib) in MM Early preclinical studies with PS-341 in MM were conducted on human myeloma cell lines and on freshly isolated cells from patients with MM. Results of these studies showed that pharmacologically achievable doses of PS-341 directly inhibited the proliferation of human myeloma cell lines, which were both sensitive and refractory to cytotoxic agents (including melphalan, doxorubicin, mitoxantrone and dexamethasone), and induced caspase-dependent apoptosis of myeloma cell lines and primary patient MM cells, regardless of p21, p27 or p53 expression. 9 MM cell lines were up to 40 times more sensitive to the proapoptotic effects of PS-341 than were peripheral blood mononuclear cells from healthy individuals. 9 PS-341 also inhibited NF-kB activation in tumor necrosis factor (TNF)-atreated MM cells by blocking the degradation of the inhibitor protein I-kBa and overcame the resistance to apoptosis in MM cells conferred by IL-6. 9, 11, 28 Furthermore, PS-341 inhibited binding of MM cells to BMSCs and abrogated the NF-kBdependent transcription and secretion of IL-6 in BMSCs. 9 Mechanisms mediating the antimyeloma activity of PS-341 were investigated at the molecular level. Analysis of gene expression profiles of PS-341-treated cells indicated that this Figure 1 Myeloma-host stromal cell interactions and related signaling cascades. Binding of myeloma cells to BMSCs plays a critical role in the pathogenesis of MM and represents a novel target for effective treatment strategies to overcome conventional drug resistance. As a result of myeloma-stromal cell interactions, transcription and secretion of several cytokines, including IL-6, insulin-like growth factor (IGF)-1 and VEGF, are enhanced in both BMSCs and myeloma cells. These cytokines activate ERK, JAK/STAT3 and/or PI3-K/Akt signaling pathways and their downstream targets, which include cytokines (e.g., IL-6, IGF-1 and VEGF) and antiapoptotic proteins (Bcl-xL, IAPs, Mcl-1) in myeloma cells. Furthermore, adhesion of myeloma cells to BMSCs activates the transcription factor NF-kB, subsequently promoting the secretion of cytokines, primarily IL-6 and antiapoptotic proteins and also upregulating the expression of adhesion molecules on both myeloma cells and BMSC, further enhancing myeloma-stromal cell interactions and cytokine secretion. From Hideshima et al. 19 Reproduced with permission from the American Society of Clinical Oncology. 30 Furthermore, activation of caspase-3 also induced DNA damage, with subsequent phosphorylation of p53 and the degradation of MDM2. 30 Importantly, these effects were induced by PS-341 in a timeand dose-dependent fashion, and all occured with PS-341 serum levels that are achieved in clinical practice.
The activity of PS-341 also was investigated in a murine MM xenograft model. 26 Results showed that this agent induced a significant inhibition of tumor growth, including several complete tumor regressions, and doubled the survival of treated mice compared with controls. In addition to inhibition of tumor growth and induction of apoptosis in vivo, PS-341 also decreased neovascularization of the tumor, supporting the antiangiogenic activity of the drug.
Chemosentisization and circumvention of drug resistance by proteasome inhibition
Activity of NF-kB may be constitutively increased in tumor cells and is associated with chemotherapy resistance, [31] [32] [33] confirming the importance of inhibiting NF-kB as an effective target for cancer therapy. Specifically, in preclinical studies, it was demonstrated that myeloma cells had increased NF-kB activity compared with normal hematopoietic stem cells. 10, 31 Likewise, chemoresistant MM cell lines were shown to have increased NF-kB activity compared with chemosensitive MM cell lines. 10, 31 Inhibition of NF-kB activity by PS-341 markedly suppressed the in vitro growth of tumor cells from MM patients and of MM cell lines. 9 Inhibitory effects of PS-341 on the growth of MM cells were enhanced by dexamethasone, whereas IL-6 failed to protect MM cells from PS-341-induced apoptosis. 9 In addition, PS-341 at subtoxic concentrations markedly enhanced the sensitivity to doxorubicin and melphalan in both drug-sensitive and resistant MM cell lines and of primary patient MM cells. 10, 11 Importantly, the combination of PS-341 with anthracyclines or melphalan had no significant cytotoxic effects on CD34-selected bone marrow or peripheral blood mononuclear cells from normal donors. Studies of gene expression profiling and proteomic analysis to characterize the effect of proteasome inhibition on the transcriptional profile of MM cells demonstrated that PS-341, in addition to suppressing the expression of antiapoptotic proteins, downregulates the transcripts for several effectors of the protective cellular response to genotoxic stress, thereby restoring sensitivity to DNA-damaging cytotoxic drugs. 11, 29 Thus, many factors are likely to contribute to reversal of chemotherapy resistance induced by PS-341, including inhibition of NF-kB activity and related downregulation of antiapoptotic protein expression, downregulation of other resistance pathways including the p44/42 mitogenactivated protein kinase (MAPK) pathway, interference with the protective interaction between myeloma cells and BMSCs, and attenuation of the protective cellular response to genotoxic stress.
Phase II and III studies of single-agent bortezomib in advanced refractory/relapsed MM Preclinical studies and phase I clinical trials 34 showing the activity of bortezomib against MM prompted the initiation of phase II and III studies aimed at investigating the safety and activity of this agent in patients in whom prior treatment strategies, including stem cell transplantation, had failed (Table 1) . 35 Following these studies, the phase III APEX (Assessment of Proteasome Inhibition for Extending Remissions) trial of singleagent bortezomib vs high-dose dexamethasone for relapsed MM was initiated (Table 1) . 37 Results of this study, the largest in MM to date, provided demonstration of the superiority of bortezomib over dexamethasone in terms of increased Xpartial remission (PR) rate (38%, including 6% complete remission (CR), according to Bladé criteria), 38 extended time to progression (TTP) (6.22 months), and longer duration of overall survival (OS) (1-year rate, 80%). The clinical benefits of single-agent bortezomib for the treatment of relapsed MM were recently confirmed with an extended follow-up of 22 months; updated results showed that the XPR rate increased to 43% and median OS was 29.8 months (Richardson PG, Blood 2005; 106: 715a, abstract). In addition, a subgroup analysis showed that the benefits of bortezomib were greatest among patients who experienced first relapse (Sonneveld P, Haematologica 2005; 90 (suppl 2): 159, abstract) ( Table 1) . Among these patients, the overall probability of XPR was 45% with bortezomib compared with 26% with dexamethasone alone, median TTP was 7 months vs 5.6 months, respectively and 1-year probability of OS was 89 vs 72%, respectively. Based on these results, in 2005 the FDA and the EMEA approved an expanded indication for bortezomib use in MM patients who have received at least one prior line of therapy. In the European Union, marketing authorization for second-line use of bortezomib includes patients who have already undergone or are unsuitable for bone marrow transplantation.
In addition to these relevant data, subgroup analyses performed in the context of SUMMIT and APEX trials supported the view that bortezomib is an effective salvage therapy even in the presence of adverse prognostic variables, such as elevated b 2 -microglobulin levels 39 and chromosome 13 abnormalities (del(13)) (Jagannath S, Haematologica 2005; 90 (suppl 2): 248, abstract). In particular, a matched-pairs analysis of 21 patients carrying metaphase-defined del(13) compared with 41 patients lacking this chromosomal abnormality was performed in the context of the APEX trial. Results showed that in the bortezomibtreated subgroup, del (13) was not associated with a lower rate of response or shorter OS, in contrast to the markedly decreased survival observed for del(13)-positive patients who were treated with dexamethasone (Jagannath S, Haematologica 2005; 90 (suppl 2): 248, abstract). In another study, similar rates of responses (XPR) were obtained among patients with or without del (13) , as detected by fluorescence in situ hybridization, Finally, studies of long-term treatment with bortezomib 40 and of bortezomib therapy in patients with impaired renal function 41 showed that under these particular conditions, the toxicity profile of the drug was not different from that observed in the original trials or in patients with normal renal function. Among 24 patients with relapsed MM and advanced renal failure, most of whom were receiving hemodialysis at the time of bortezomib administration, treatment with this agent given alone or in combination with other drugs yielded an overall XPR rate of 78%, including 34% CR or near CR (nCR; disappearance of M-protein at routine electophoresis but positive immunofixation) (Chanan-Khan A, Blood 2005; 106: 716a, abstract). Thus, advanced renal failure requiring hemodialysis per se is not a strict contraindication to bortezomib use, although careful monitoring of these patients is recommended.
Adverse events and toxicities
Toxicities attributable to bortezomib as single-agent therapy for patients with advanced relapsed and/or refractory MM are generally manageable and reversible. Most common side effects include gastrointestinal symptoms, fatigue, thrombocytopenia, sensory neuropathy, vomiting and anorexia. [35] [36] [37] Several of these toxicities, such as diarrhea, peripheral neuropathy and vomiting, were observed more frequently with the dose of 1.3 mg/m 2 compared with 1.0 mg/m 2 . 36 Gastrointestinal symptoms were generally mild or moderate and could be managed with routine support. Thrombocytopenia was the most common severe adverse event, with an average occurrence in approximately 30% of patients; it occurred more frequently in patients with low platelet counts at baseline 35, 42 and was typically transient, with recovery of platelet counts toward baseline during the rest period of each cycle. [35] [36] [37] 42 As a result of the short duration of thrombocytopenia, in the APEX trial the risk of bleeding events among patients receiving bortezomib was not superior to that seen in patients treated with dexamethasone alone (Lonial S, Blood 2005; 106: 970a, abstract). When clinically indicated, platelet transfusion, rather than bortezomib dose reduction, is recommended in patients with severe thrombocytopenia (Lonial S, Blood 2005; 106: 970a, abstract). Clinically, cumulative peripheral neuropathy was the most important toxicity of bortezomib therapy for patients with advanced and refractory MM. Combined safety data from phase II and III SUMMIT and APEX trials reported a 31-36% incidence of peripheral neuropathy, which was grade 3-4 in 8-12% of patients, and occurred more frequently in patients with neurological symptoms at baseline. [35] [36] [37] In the APEX study, bortezomib dose modifications or discontinuation were required in 79% of 91 patients with grade X2 neuropathy (San Miguel JF, Blood 2005; 106: 111a, abstract). Among these 91 patients, improvement in neurological symptoms was noted in 9% of cases, whereas 55% of patients had complete resolution of peripheral neuropathy to baseline within 2-3 months from the last bortezomib dose. With early detection of peripheral neuropathy and the use of an algorithm for dose reductions or discontinuation, most patients can promptly improve or recover from their neurological symptoms. Moreover, the use of garbapentin or amitriptylin, in addition to vitamin supplements and topical application of capsaicin cream, may be of further clinical benefit.
Phase II studies of bortezomib combined with other agents in advanced refractory/relapsed MM Results of preclinical studies showing that bortezomib enhanced the sensitivity of myeloma cells to conventional chemotherapy 10, 11 and added to the antimyeloma activity of dexamethasone 9 provided the rationale for the development of combinations trials for the treatment of patients with disease relapsed or refractory to multiple prior therapies. In these trials, various combinations of bortezomib with DNA-damaging drugs, such as doxorubicin and melphalan and/or dexamethasone or thalidomide, have been explored in an attempt to reverse chemotherapy resistance and to expand the therapeutic armamentarium for advanced MM (Table 1) 35, 36, 43, 44 In the phase II SUMMIT and CREST studies, patients with suboptimal response to single-agent bortezomib (1.3 or 1.0 mg/ m 2 ) were permitted to subsequently receive added dexamethasone (20 mg) on the day of and day after each bortezomib dose (Table 1) . 35, 36 An improved response (Xminimal response (MR)) was observed in 11-18% of patients, confirming the additive effect of these two agents previously found in preclinical studies. 9 The optimal combination of bortezomib and melphalan was investigated in two phase I-II dose-escalation studies (Popat R, Blood 2005; 106: 718a, abstract). 43 In one of these trials, dose escalation of the two drugs proceeded to the bortezomib 1.0 mg/ m 2 and oral melphalan 0.25 mg/kg cohort, in which two episodes of dose-limiting toxicity (DLT) were observed 43 ( Table 1) . Myelosuppression was the most common severe toxicity and occurred more frequently among patients with baseline cytopenia; the overall XMR rate was 68%. In another study, standard-dose bortezomib (1.3 mg/m 2 ) was combined with intravenous melphalan at an initial dose of 10 mg/m 2 . However, owing to excessive hematologic toxicity, in subsequent cohorts the starting dose of melphalan was 2.5 mg/m 2 , with planned escalation up to the maximum dose of 7.5 mg/m 2 (Popat R, Blood 2005; 106, 718a, abstract). Among 21 evaluable patients, the overall XMR rate across all treatment levels was 62% and increased up to 76% when dexamethasone was added to bortezomib and melphalan. Six episodes of grade 3 neuropathy were reported, with five resulting in study withdrawal. Based on these favorable data and in light of promising results of combined bortezomib-thalidomide therapy, a phase I-II dose-escalation study aimed at exploring the toxicity and activity of a regimen including bortezomib, melphalan, prednisone and thalidomide was recently initiated (Palumbo A, Blood 2005; 106: 717a, abstract) ( Table 1) .
In another phase II study, the combination of standard-dose bortezomib (1.3 mg/m 2 ) with dexamethasone and continuous low-dose oral cyclophosphamide (50 mg/day) was investigated in a series of 50 patients with relapsed MM (Kropff M, Blood 2005; 106: 716a, abstract) (Table 1) . Notably, 78% of patients had relapsed after high-dose melphalan and 46% had del (13) . The overall XMR rate was 90%, including 12% CR, and median event-free survival (EFS) was 12 months. Severe non-hematologic toxicities, including infections (24.5%) and peripheral neuropathy (18.9%), were comparable to those previously reported with single-agent bortezomib.
Preclinical studies showing that bortezomib suppresses the antiapoptotic p44/p42-MAPK pathway, which is activated by anthracyclines, 45 and inhibits chemotherapy-mediated activation of NF-kB, highlighted the potential usefulness of combining bortezomib and doxorubicin for the treatment of advanced refractory MM. In this light, a phase I study of escalated-dose bortezomib (0.9-1.5 mg/m 2 ) and pegylated liposomal doxorubicin (30 mg/m 2 ) was conducted in 42 patients with advanced haematologic malignancies, including 24 patients with MM (Table 1) . 44 Among 22 MM patients who were evaluable for response, 16 (73%) achieved XPR, including 36% XnCR. Importantly, some of the patients achieving XnCR had anthracycline-refractory MM, confirming that bortezomib may restore the in vivo sensitivity of myeloma cells to conventional chemotherapy.
On the basis of the apparent lack of cross-resistance of bortezomib and thalidomide, a phase I-II dose-escalation study of both these agents combined with dexamethasone (VTD) was designed for the treatment of patients with advanced and refractory MM (Zangari M, Blood 2005; 106: 717a, abstract) (Table 1) . Eighty-five patients entered the study; of these patients, 74% had cytogenetic abnormalities, including del(13) in 47% and 84% had previously received a single autologous transplantation. In addition, 73% of patients had prior exposure and resistance to thalidomide. With bortezomib 1.0 mg/m 2 , no maximal-tolerated dose (MTD) of thalidomide was reached; with bortezomib 1.3 mg/m 2 , the MTD of thalidomide was 150 mg/day. Myelosuppression was the most frequent grade 3-4 toxicity. Overall, 70% of patients experienced XMR and 55% achieved XPR, including 16% XnCR. Median EFS and OS were 9 and 22 months, respectively. Based on remarkable activity demonstrated in patients with high-risk MM, the VTD combination recently has been included in front-line treatment strategies for newly diagnosed disease.
A phase II study evaluated whether the addition of doxorubicin to VTD (VATD) would overcome resistance to bortezomib-based regimens in 22 patients in whom prior therapy with thalidomide (100% of patients) or single-agent bortezomib (95% of patients) or VTD (45% of patients) had failed (Hollmig K, Blood 2005; 104: 659a, abstract) ( Table 1) . Of these patients, 14 were assessable for response and 50% of them achieved PR, suggesting that doxorubicin can be successfully added to VTD.
Another phase II study explored the use of bortezomib in combination with doxorubicin and thalidomide (VDT) as salvage therapy in 21 patients in whom a median of three prior therapies (range, 1-7), including stem cell transplantation (29%), thalidomide (57%) and bortezomib (19%), had failed (Chanan-Khan A, Haematologica 2005; 90 (suppl 2): 253, abstract) ( Table 1) . Among 14 patients who could be evaluated, the XPR rate was 57%, including 14% CR. Grade 3-4 thrombocytopenia and neuropathy were reported in 24 and 9.5% of patients, respectively.
Preclinical studies showing that lenalidomide (known as CC-5013 or Revlimid), a potent thalidomide analog, potentiates the apoptotic effects of bortezomib 46 provided the rationale for a phase I dose-escalation study of both these agents in relapsed and refractory MM (Richardson P, Blood 2005; 106: 110a, abstract) ( Table 1 ). The maximum dose levels planned for bortezomib and lenalidomide in the absence of DLT were 1.3 mg/m 2 and 20 mg/day. At the time of the latest report, 24 patients had received a median of seven cycles of bortezomib (1.0-1.3 mg/m 2 ) combined with lenalidomide (5-15 mg/day). Two DLTs were observed at bortezomib 1.3 mg/m 2 and lenalidomide 10 mg/day (one patient) and 15 mg/day (one patient). Twenty-one patients were assessable for response; of these patients, 11 (52%) achieved XPR.
Bortezomib (1.0-1.3 mg/m 2 ) appeared to be safe even when added to high-dose melphalan (100-250 mg/m 2 ) in preparation for autologous transplantation (Hollmig K, Blood 2004; 104: 266a, abstract) ( Table 1 ). This novel, intensified conditioning regimen was tested in a series of 37 patients, most of whom had high-risk MM. Among 27 patients evaluable for response, the XPR rate was 36%, including 26% CR. Non-hematologic toxicity included pneumonia/sepsis (38%), diarrhea (30%), febrile neutropenia (13.5%) and mucositis (13.5%). Another study evaluated the tolerability of single-agent bortezomib as early consolidation therapy following autologous transplantation (Peles S, Blood 2005; 106: 905a, abstract). Forty patients were enrolled; of these patients, 33 received at least one posttransplantation cycle of standard-dose bortezomib (1.3 mg/m 2 ) and were evaluated. No grade 3-4 myelotoxicity was observed, whereas treatment-emergent neuropathy was seen in 9% of patients, leading to bortezomib discontinuation in two of these patients. Notably, 42.4% of patients experienced reactivation of varicella zoster virus.
Finally, preliminary experiences conducted in a small series of patients receiving allogeneic stem cell transplantation suggest that bortezomib may be an effective option both as consolidation therapy for patients with post-transplantation residual disease and as salvage therapy for patients who experience relapse or progression (Giralt S, Blood 2004; 104: 459a, abstract) ( Table 1) .
Phase II studies with bortezomib alone or combined with other agents in previously untreated MM Following the remarkable success and tolerable toxicity profile of bortezomib in advanced refractory or relapsed MM, numerous clinical trials have been designed to assess the activity and toxicity of this agent as front-line therapy for younger and elderly patients with newly diagnosed disease. In these studies, the role of bortezomib was explored as singleagent therapy or, more frequently, in combination with other drugs ( 47, 48 In particular, great efforts have been devoted to the development of bortezomib-based combination regimens aimed at enhancing the rate, rapidity and magnitude of response in patients who are candidates to receive autologous stem cell transplantation. In addition to response, important end points of these studies also included safety and toxicity profile, with particular considerations for harvesting peripheral blood stem cells (PBSCs).
The toxicity, particularly neurologic, and activity of singleagent bortezomib at standard dose (1.3 mg/m 2 ) in previously untreated MM patients was evaluated in a phase II trial (Richardson P, Blood 2005; 106: 716a) ( Table 2 ). In this study, the addition of dexamethasone to bortezomib was not permitted. Among 65 patients who were assessable for safety, the incidence of peripheral neuropathy was 55%, mostly grade 1-2. Interestingly, subclinical small fiber neuropathy at baseline was documented by nerve conduction studies in 17 of 34 patients (50%), suggesting that underlying neuropathy is more common in MM than is generally appreciated. Among 60 assessable patients, XPR rate after two or more cycles was 28%, Table 2 Summary of phase I-II trials of bortezomib alone or in combination with other agents in previously untreated patients with multiple myeloma 
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Abbreviations: B, bortezomib; CR, complete response; d, day; Dex, dexamethasone; Dox, doxorubicin; M, melphalan; nCR, near complete response; P, prednisone; PR, partial response; T, thalidomide; VGPR, very good partial response; wk, week.
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including 10% CR; in addition, MR was seen in 25% additional patients.
In another phase II trial, patients with newly diagnosed MM who did not respond favorably to single-agent bortezomib at standard dose (1.3 mg/m 2 ) were permitted to receive dexamethasone (40 mg) on the day of and day after each bortezomib dose (Jagannath S, Blood 2005; 106: 231a, abstract). Fifty patients were enrolled, 48 of whom were evaluated for response. Of these 48 patients, 12 received single-agent bortezomib and 36 received bortezomib combined with oral dexamethasone ( Table 2 ).The best overall response rate (XPR) was 90%, including 20% XnCR, and was seen after two cycles in 50% of patients, after four cycles in 79% ,and after six cycles in 90% of patients. The addition of dexamethasone to bortezomib resulted in upgraded responses in 64% of patients, the majority being improvements from either stable disease or MR to PR. Among 49 patients assessable for toxicity, grade X2 and grade 3 sensory neuropathy were seen in 37 and 12% of cases, respectively. Bortezomib 1.3 mg/m 2 combined with dexamethasone as primary therapy in preparation for autologous stem cell transplantation was further explored in a study conducted by the Intergroupe Francais du Myélome (Harrousseau J, J Clin Oncol 2005; 23 (suppl 16): 598, abstract) ( Table 2) . Among 48 evaluable patients, the overall response rate (XPR) was 67%, including 17% CR and 13% very good PR. Peripheral neuropathy was observed in 29% of patients and was grade 3 in 9%; one patient required treatment discontinuation owing to neuropathy.
A novel regimen consisting of the combination of bortezomib 1.3 mg/m 2 with dexamethason and escalating doses of doxorubicin (0-9 mg/m 2 ), referred to as PAD, was investigated in a series of 21 patients with newly diagnosed MM who were candidates to undergo autologous stem cell transplantation (Table 2) . 47 The overall response rate was 95%; the rate of XnCR increased from 29% after PAD to 57% after autologous transplantation. Sensory and painful neuropathies were the most frequent adverse events, and both occurred in 48% of patients; in all but one of these patients, neurologic toxicity was grade 1.
In an attempt to decrease the frequency of neuropathy, in a subsequent cohort of 19 patients, the dose of bortezomib was reduced from 1.3 to 1.0 mg/m 2 , whereas doxorubicin was administered at the same escalating doses (Popat R, Blood 2005; 106: 717a, abstract). (Table 2 ). At the time of report, 19 patients were evaluable. Response to the reduced PAD regimen was comparable to that previously observed with the higher-dose regimen; no grade 3-4 neuropathy was seen. Fifteen patients completed all four cycles of therapy; among non-completers, one patient died of pneumonia related to myeloma bone disease and one developed line sepsis.
The efficacy and safety of bortezomib 1.0-1.9 mg/m 2 , thalidomide 100-200 mg daily and dexamethasone (VTD) were investigated in a series of 38 consecutive newly diagnosed MM patients (Wang M, Blood 2005; 106: 231a, abstract) ( Table 2) . Of these patients, the majority were candidates to receive subsequent autologous transplantation. Bortezomib was given at the initial dose of 1.3 mg/m 2 in 45% of patients, at 1.5 mg/m 2 in 29% of patients, and at X1.6 mg/m 2 in the last 26% of patients. The overall response rate across all treatment levels was 92%, including 18% CR, and was not influenced by the dose of bortezomib. Importantly, time to response was p1.5 months, so that two cycles of VTD were necessary to prepare the patients for subsequent autologous transplantation. Because of the short treatment duration, adverse events were generally mild and reversible.
Further exploration of the VTD combination as primary remission induction therapy for patients with newly diagnosed MM was performed in the context of the Total Therapy 3 (TT3) program (Barlogie B, Blood 2005; 106:337a, abstract). In this study, the VTD regimen was added to 4-day continuous infusions of cisplatin, doxorubicin, cyclophosphamide and etoposide (PACE) in preparation for double autologous transplantation. Compared with the predecessor trial Total Therapy 2 (TT2), which included thalidomide (n ¼ 314 patients), TT3 was more effective in inducing XnCR (64 vs 81%, respectively), partly due to a higher percentage of patients completing the intended two transplantations (68 vs 78%, respectively). Treatment-related mortality at 12 months was not different between the two trials.
Based on the in vitro and in vivo synergy of bortezomib with melphalan, the GEM/PETHEMA group (Spanish Myeloma Group) designed a phase I-II dose-escalation study of bortezomib combined with melphalan and prednisone (V-MP) as firstline treatment of elderly (X65 years) MM patients who were not candidates to receive autologous stem cell transplantation (Mateos M, Blood 2005; 106: 232a, abstract) ( Table 2 ). The study comprised a dose-finding phase I aimed at exploring the optimal dose of bortezomib (1.0 or 1.3 mg/m 2 ) and a subsequent phase II to evaluate the toxicity and efficacy of V-MP (Table 2) . In phase I, no DLTs were observed, and the recommended dose of bortezomib was 1.3 mg/m 2 for subsequent phase II. Sixty patients were enrolled, 53 of whom were evaluable for efficacy. After a median of seven cycles, the overall best response (XPR) rate was 88%, including 43% XnCR. Most frequent grade 3-4 toxicities among patients receiving X3 cycles included neutropenia (24%) and thrombocytopenia (17%); severe peripheral neuropathy was observed in 6% of cases.
Effect of bortezomib on stem cell collection and engraftment
Over the last decade, front-line therapy with vincristine, doxorubicin and dexamethasone (VAD) or dexamethasone alone has been the standard of care for younger MM patients in whom autologous stem cell transplantation is planned. Advantages in using VAD or VAD-like regimens in this setting include the rate and rapidity of response and, more importantly, the lack of toxicity on normal hematopoietic stem cells. More recently, novel agents targeting both the myeloma clone and the bone marrow microenviroment have become available, providing the framework for the development of alternative therapies to reduce tumor cell mass in preparation for autologous transplantation. [49] [50] [51] However, novel treatments can be considered appropriate provided that response is maximized, the toxicity profile is low, and subsequent stem cell harvesting is not adversely affected. This latter concern is of particular relevance and has represented one of the most important end points of studies conducted so far with bortezomib, alone or in combination with other agents, as first-line therapy for patients with newly diagnosed MM (Table 3) . 48 In one study, bortezomib 1.3 mg/m 2 with or without dexamethasone was shown to be feasible as induction therapy prior to autologous stem cell transplantation. 48 Twenty-three patients underwent successful stem cell mobilization with G-CSF alone, with a median of 12.55 Â 10 6 /kg (range, 5.11-40.37 Â 10 6 /kg) CD34 þ cells mobilized during 2-3 collection days. Post-transplantation engraftment was prompt in all patients. In another study, 53 previously untreated patients who were candidates for autologous stem cell transplantation received four 3-week cycles of bortezomib 1.3 mg/m 2 followed by stem cell harvest with G-CSF alone (Harousseau J, J Clin Oncol 2005; 23 (suppl 16): 598, abstract). PBSC harvest was successful in 42 out of 45 patients who underwent the procedure and the median number of collected CD34 þ cells was 6.7 Â 10 6 /kg. Sufficient stem cells were collected for two transplants in 78.5% of patients.
The efficiency of PBSC collection following four 3-week cycles of PAD recently was reported in a series of 21 patients. 47 Of these patients, 20 mobilized a median of 3.75 Â 10 
Adverse events and toxicities
Overall, severe adverse events registered with the use of bortezomib alone or in combination with other agents for the treatment of newly diagnosed MM have been modest and manageable. Grade 3-4 sensory peripheral neuropathy or neuropathic pain were reported in up to 16% of patients (Richardson P 47, 48 This incidence is similar to that of previous studies performed in heavily pretreated patients with advanced refractory or relapsed disease. 35 ,37 Table 3 Collection of peripheral blood stem cells following front-line therapy with bortezomib alone or in combination with other agents 47, 48 probably a reflection of better bone marrow reserve in previously untreated patients. Non-neutropenic infections were observed in fewer than 10% of patients. However, episodes of shingles were reported in 19% of patients receiving the PAD regimen, 47 suggesting the need for appropriate prophylaxis, at least for patients treated with bortezomib and cytotoxic drugs.
Conclusion
Over the last decade, new insights into the biology of MM have provided the framework for the development of novel therapies to overcome drug resistance. In particular, recognition of the pivotal role of the bone marrow microenvironment in promoting myeloma cell growth, survival, drug resistance and migration has allowed for identification of specific therapeutic strategies targeting myeloma-host stromal cell interactions and cytokine secretion and their sequelae in the bone marrow milieu. The first-in-class proteasome inhibitor bortezomib is an excellent example of this novel class of agents that has quickly translated from the bench to the bedside. Remarkable activity seen with bortezomib as a single agent in advanced refractory/relapsed MM has validated the proteasome as an effective target in the treatment of cancer and has led to approval for bortezomib use in patients for whom prior therapies have failed. Based on preclinical and clinical data demonstrating that bortezomib adds to the antimyeloma activity of other agents, including dexamethasone, DNA-damaging drugs, thalidomide and lenalidomide, more recent studies of combination therapies have been initiated in patients with both refractory/relapsed and newly diagnosed MM in an attempt to expand the therapeutic armamentarium for this still-devastating malignancy. These studies will provide important information concerning the best sequence and combination of these agents and, it is hoped, will reveal the optimal treatment strategies to improve the prognosis of patients with MM in the near future.
